Ampio Announces the Presentation of a Publication on Ampion(TM), its Drug Candidate to Address Human Inflammation, at the American Association of Orthopedic Surgery

About the Ampion(TM) in Knee (AIK) Trial
In this study, Ampion(TM) is injected into the knees of patients with osteoarthritis of the knee in conjunction with standard therapy, including steroids, aiming to demonstrate a reduction in pain and improved range of motion compared to placebo. The observation period in this study is only 72 hours, thus results of this trial are anticipated to be available in the short term.

About Ampion(TM)
Ampion(TM) is a patented small molecule with non- steroidal anti-inflammatory and analgesic properties that is naturally produced by humans in response to injury. Because it is present in commercially available human serum albumin which has been given to millions of people over several decades, it can be considered to be a biological. MarketWatch